Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Total Liabilities & Equity
ÂĄ1.7B
CAGR 3-Years
15%
CAGR 5-Years
4%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Total Liabilities & Equity
ÂĄ62.7B
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
25%
PeptiDream Inc
TSE:4587
Total Liabilities & Equity
ÂĄ93.4B
CAGR 3-Years
50%
CAGR 5-Years
38%
CAGR 10-Years
32%
Takara Bio Inc
TSE:4974
Total Liabilities & Equity
ÂĄ125.3B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
3%
CAGR 5-Years
30%
CAGR 10-Years
24%
C
Cuorips Inc
TSE:4894
Total Liabilities & Equity
ÂĄ6.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
1.7B JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Total Liabilities & Equity amounts to 1.7B JPY.

What is Perseus Proteomics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
4%

Over the last year, the Total Liabilities & Equity growth was -34%. The average annual Total Liabilities & Equity growth rates for Perseus Proteomics Inc have been 15% over the past three years , 4% over the past five years .

Back to Top